Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.6 USD | +1.10% | -2.44% | -27.31% |
09/04 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
03/04 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Denali Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Denali Therapeutics Inc.
UBS | |
B. Riley | |
Citigroup | |
Wedbush | |
Oppenheimer | |
Morgan Stanley | |
Evercore ISI | |
SVB Securities LLC | |
Cowen | |
Berenberg Bank | |
BofA Securities | |
Goldman Sachs | |
SMBC Nikko | |
HC Wainwright | |
Cantor Fitzgerald |
EPS Revisions
- Stock Market
- Equities
- DNLI Stock
- Consensus Denali Therapeutics Inc.